A Study to Compare the Effect of SB3 and Herceptin® in Women With HER2 Positive Breast Cancer
Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
A Phase III Randomised, Double-Blind, Parallel Group, Multicentre Study to Compare the
Efficacy, Safety, Pharmacokinetics and Immunogenicity between SB3 (proposed trastuzumab
biosimilar) and Herceptin® in Women with Newly Diagnosed HER2 Positive Early or Locally
Advanced Breast Cancer in Neoadjuvant Setting